Navigation Links
Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
Date:9/15/2008

ncer after failure of standard treatment, including Sutent(R) (sunitinib) or Nexavar(R) (sorafenib), or both.

Earlier this year, interim results from RECORD-1 presented at the American Society of Clinical Oncology Congress were used to submit regulatory applications for RAD001 as a treatment for metastatic renal cell carcinoma (RCC). RAD001 was granted priority review by the US Food and Drug Administration. FDA priority review status is granted to therapies that could potentially fill a currently unmet medical need and accelerates the standard review time from ten to six months.

"We are encouraged by the continued benefit RAD001 provided to patients with advanced kidney cancer in this trial," said David Epstein, CEO and President of Novartis Oncology. "Novartis is committed to bringing this new, innovative therapy to market and to exploring the potential of RAD001 beyond this specific treatment setting."

RAD001 is a once-daily oral therapy that may offer a new approach to cancer treatment by continuously inhibiting the mTOR protein, a central regulator of cell division and tumor blood vessel growth. Data suggest RAD001 has clinical activity as a single agent or in combination with other therapies in multiple types of cancer, including pancreatic neuroendocrine tumors, breast, gastric, lung and lymphoma.

RECORD-1 results

RECORD-1 is the largest Phase III clinical trial investigating the effects of an oral mTOR inhibitor in metastatic RCC. It is a randomized, double-blind, placebo-controlled multicenter trial of more than 400 patients with RCC whose cancer worsened despite prior treatment including Nexavar or Sutent, or both. In addition, prior therapy with Avastin, interferon and interleukin-2 was allowed.

The primary endpoint of RECORD-1 was progression-free survival (PFS) assessed via a blinded, independent central review and defined as the amount of time between randomization and first documented disease progression or dea
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
2. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
3. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
4. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
5. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
8. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
9. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
10. Most Cancer Treatment Studies Arent Published, Study Finds
11. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... and ensure faster access to client ... ... DATA ), a technology and services company focused on global,eClinical solutions ... efficiency for end-users with the,DATATRAK eClinical(TM) 2008 Q1 Release., ...
... needle-free vaccine,platform that elicits a robust immune response ... been awarded a U.S. patent. The University of,Michigan ... from the,university, licenses the patent and its associated ... nanoemulsion,technology, have elicited a dramatic immune response in ...
Cached Medicine Technology:DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0 2DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0 3DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0 4DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0 5New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity 2New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity 3
(Date:4/20/2014)... Calif. A single type of cell in the ... of invasive bladder cancer, according to researchers at the ... in mice, is the first to pinpoint the normal ... cancers. It,s also the first to show that most ... just one cell, and explains why many human bladder ...
(Date:4/18/2014)... The Gerontologist reports that among older ... decrease in anxiety about death and increases in life ... In particular, listening to gospel music is associated with ... in sense of control. , These associations are similar ... of both low- and high-socioeconomic status. , The article, ...
(Date:4/18/2014)... worst memories? How did it make you feel? According ... personal experience, such as how sad you were or ... especially when you can,t stop thinking about it. ... the context of the memories, rather than how you ... alleviate the negative effects of these memories, a new ...
(Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Religious music brings benefit to seniors' mental health 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... Shareholders Approve Dividend Payment of EUR 0.40 per ... ended,the financial year 2007 with a positive result. In ... EBITDA) of,EUR181.6m. For the first quarter of the current ... 18.2% to EUR 239.1m, with a 20.4%,increase in operating ...
... 23 MDNG, a publication that,reaches nearly a ... online discussion that will provide physicians an opportunity,to ... whose unique,practice model has made him a household ... 28, 2008, at 8:00 p.m. EDT at, http://www.mdnglive.com/chat/JayParkinson ...
... EXTON, Pa., May 23 Kensey Nash Corporation,(Nasdaq: ... 12th Annual Spring,Investor Conference at the Grand Hyatt New ... 2008., Douglas G. Evans, Kensey Nash,s COO, will ... To hear the live,webcast of the Kensey Nash presentation ...
... 40,000 Americans each year , , FRIDAY, May 23 (HealthDay ... lungs that,s fatal within a few years of diagnosis ... researchers say daily use of the drug pirfenidone improved ... with the illness, called idiopathic pulmonary fibrosis (IPF). , ...
... HARBIN, China, May 23 /Xinhua-Prnewswire-FirstCall/ -- China Sky ... marketer and,distributor of pharmaceutical, medicinal and diagnostic products ... been approved for listing on,the American Stock Exchange ... under the symbol "CSY". This approval is contingent ...
... "American Right To Life is,offering attorney James Bopp ... "if he can name a single justice on the ... unborn child has a,right to life, whether in a ... after Bopp and NRTL refused President Ronald,Reagan,s offer to ...
Cached Medicine News:Health News:Gerresheimer Continues Expansion Course 2Health News:MDNG Offers Free Online Discussion With Maverick Physician Jay Parkinson, M.D. 2Health News:Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference 2Health News:Drug for Deadly Lung Disease Shows Promise 2Health News:Drug for Deadly Lung Disease Shows Promise 3Health News:China Sky One Medical, Inc. Approved for Listing on the American Stock Exchange 2Health News:$10,000 Offer to National RTL From American RTL to Name 'One' Pro-Life Justice 2
... A lower cost alternative to Equalizers, the ... transfers between two different vessel configurations. With the ... can be quickly and easily adjusted for test ... Ergonomic Design for Unparalleled Comfort Pick ...
... Expandable Tip System A lower cost alternative ... to perform multi-sample transfers between two different vessel ... knob, tip spacing can be quickly and easily ... 96 well plates. Ergonomic Design for Unparalleled ...
... Well Plate Capability The Equalizer 384 ... Equalizerexpandable and equal tip spacing, choice of two ... In addition, this model allows you to evenly ... and accessing many gels and for use with ...
... With 384 Well Plate Capability The ... the original Equalizerexpandable and equal tip spacing, choice ... calibration capabilities. In addition, this model allows you ... for loading and accessing many gels and for ...
Medicine Products: